Mesenchymal stem cell therapy for intractable neonatal disorders
Mesenchymal stem cell (MSC) transplantation has emerged as a new promising therapeutic strategy for the treatment of intractable and devastating neonatal disorders with complex multifactorial etiologies, including bronchopulmonary dysplasia (BPD), intraventricular hemorrhage (IVH), and hypoxic-ische...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-02-01
|
| Series: | Pediatrics and Neonatology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1875957220301984 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850262935772856320 |
|---|---|
| author | So Yoon Ahn Won Soon Park Se In Sung Yun Sil Chang |
| author_facet | So Yoon Ahn Won Soon Park Se In Sung Yun Sil Chang |
| author_sort | So Yoon Ahn |
| collection | DOAJ |
| description | Mesenchymal stem cell (MSC) transplantation has emerged as a new promising therapeutic strategy for the treatment of intractable and devastating neonatal disorders with complex multifactorial etiologies, including bronchopulmonary dysplasia (BPD), intraventricular hemorrhage (IVH), and hypoxic-ischemic encephalopathy (HIE). In response to inflammatory and noxious environments, MSCs secrete various paracrine factors that perform several reparative functions, including exerting anti-inflammatory, anti-oxidative, anti-apoptotic, and anti-fibrotic effects, to enhance the regeneration of damaged cells and tissues. In this review, we summarize recent advances in stem cell research focusing on the use of MSCs in the prevention and treatment of newborn BPD, IVH and HIE, with particular emphasis on preclinical and clinical data. |
| format | Article |
| id | doaj-art-d8bc3a55d0334fc3b3f707ea9986c22e |
| institution | OA Journals |
| issn | 1875-9572 |
| language | English |
| publishDate | 2021-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Pediatrics and Neonatology |
| spelling | doaj-art-d8bc3a55d0334fc3b3f707ea9986c22e2025-08-20T01:55:05ZengElsevierPediatrics and Neonatology1875-95722021-02-0162S16S2110.1016/j.pedneo.2020.11.007Mesenchymal stem cell therapy for intractable neonatal disordersSo Yoon Ahn0Won Soon Park1Se In Sung2Yun Sil Chang3Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Stem Cell and Regenerative Medicine Institute, Samsung Medical Center, Seoul, South KoreaDepartment of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Stem Cell and Regenerative Medicine Institute, Samsung Medical Center, Seoul, South Korea; Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, South KoreaDepartment of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South KoreaDepartment of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Stem Cell and Regenerative Medicine Institute, Samsung Medical Center, Seoul, South Korea; Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, South Korea; Corresponding author. Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro, Gangnam-Ku, Seoul, 06351, South Korea. Fax: +82 2 3410 0043.Mesenchymal stem cell (MSC) transplantation has emerged as a new promising therapeutic strategy for the treatment of intractable and devastating neonatal disorders with complex multifactorial etiologies, including bronchopulmonary dysplasia (BPD), intraventricular hemorrhage (IVH), and hypoxic-ischemic encephalopathy (HIE). In response to inflammatory and noxious environments, MSCs secrete various paracrine factors that perform several reparative functions, including exerting anti-inflammatory, anti-oxidative, anti-apoptotic, and anti-fibrotic effects, to enhance the regeneration of damaged cells and tissues. In this review, we summarize recent advances in stem cell research focusing on the use of MSCs in the prevention and treatment of newborn BPD, IVH and HIE, with particular emphasis on preclinical and clinical data.http://www.sciencedirect.com/science/article/pii/S1875957220301984stem cellsstem cell transplantationinfant, newbornclinical trial |
| spellingShingle | So Yoon Ahn Won Soon Park Se In Sung Yun Sil Chang Mesenchymal stem cell therapy for intractable neonatal disorders Pediatrics and Neonatology stem cells stem cell transplantation infant, newborn clinical trial |
| title | Mesenchymal stem cell therapy for intractable neonatal disorders |
| title_full | Mesenchymal stem cell therapy for intractable neonatal disorders |
| title_fullStr | Mesenchymal stem cell therapy for intractable neonatal disorders |
| title_full_unstemmed | Mesenchymal stem cell therapy for intractable neonatal disorders |
| title_short | Mesenchymal stem cell therapy for intractable neonatal disorders |
| title_sort | mesenchymal stem cell therapy for intractable neonatal disorders |
| topic | stem cells stem cell transplantation infant, newborn clinical trial |
| url | http://www.sciencedirect.com/science/article/pii/S1875957220301984 |
| work_keys_str_mv | AT soyoonahn mesenchymalstemcelltherapyforintractableneonataldisorders AT wonsoonpark mesenchymalstemcelltherapyforintractableneonataldisorders AT seinsung mesenchymalstemcelltherapyforintractableneonataldisorders AT yunsilchang mesenchymalstemcelltherapyforintractableneonataldisorders |